环氧化酶2抑制剂依托考昔作为结核辅助治疗损害巨噬细胞对分枝杆菌生长的控制
TBCOX2 1/2期随机临床试验采集15例接受辅助COX-2抑制剂(COX-2i)治疗的结核患者与18例对照(标准治疗)治疗开始后第56天的外周血单个核细胞,用鸟分枝杆菌体外感染模型评估巨噬细胞控制分枝杆菌的能力。COX-2i组巨噬细胞感染6天后鸟分枝杆菌载量高于对照,TNF、IL-1B、CCL4、CXCL9、CXCL10基因表达及IFN-β、S100A8/A9产生降低,提示巨噬细胞控制分枝杆菌生长能力受损。
要点
- COX-2i组巨噬细胞感染6天后鸟分枝杆菌载量高于标准治疗对照组。
- COX-2i组巨噬细胞TNF、IL-1B、CCL4、CXCL9、CXCL10基因表达低于对照。
- COX-2i组IFN-β与S100A8/A9产生低于对照,作者提出需更大临床试验评估安全性。
核心结论
- 数据提示接受COX-2i治疗的结核患者巨噬细胞控制分枝杆菌生长能力受损,可能存在不利效应。
- 作者提出需更大规模临床试验分析COX-2i作为宿主导向治疗在结核患者中的安全性。
研究设计与样本
- 1/2期随机临床试验(TBCOX2,注册号NCT02503839),比较辅助COX-2i治疗与标准治疗。
- 采集15例接受辅助COX-2i治疗的结核患者与18例对照(标准治疗)治疗开始后第56天的外周血单个核细胞。
- 用鸟分枝杆菌体外感染模型评估巨噬细胞控制分枝杆菌感染的能力,并以基因表达特征和多因子检测分析炎症反应。
主要发现
- COX-2i组巨噬细胞感染6天后鸟分枝杆菌载量高于对照组,提示其控制分枝杆菌感染的能力较对照组巨噬细胞受损。
- COX-2i组巨噬细胞TNF、IL-1B、CCL4、CXCL9、CXCL10基因表达低于对照组。
- COX-2i组IFN-β与S100A8/A9产生低于对照组。
局限性
- 作者指出需更大规模临床试验分析COX-2i作为宿主导向治疗在结核患者中的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current tuberculosis treatment regimens could be improved by adjunct host-directed therapies (HDT) targeting host responses. We investigated the antimycobacterial capacity of macrophages from patients with tuberculosis in a phase 1/2 randomized clinical trial (TBCOX2) of the cyclooxygenase-2 inhibitor etoricoxib. METHODS: Peripheral blood mononuclear cells from 15 patients with tuberculosis treated with adjunctive COX-2i and 18 controls (standard therapy) were collected on day 56 after treatment initiation. The ex vivo capacity of macrophages to control mycobacterial infection was assessed by challenge with Mycobacterium avium, using an in vitro culture model. Macrophage inflammatory responses were analyzed by gene expression signatures, and concentrations of cytokines were analyzed in supernatants by multiplex. RESULTS: Macrophages from patients receiving adjunctive COX-2i treatment had higher M. avium loads than controls after 6 days, suggesting an impaired capacity to control mycobacterial infection compared to macrophages from the control group. Macrophages from the COX-2i group had lower gene expression of TNF, IL-1B, CCL4, CXCL9, and CXCL10 and lowered production of cytokines IFN-β and S100A8/A9 than controls. CONCLUSIONS: Our data suggest potential unfavorable effects with impaired macrophage capacity to control mycobacterial growth in patients with tuberculosis receiving COX-2i treatment. Larger clinical trials are required to analyze the safety of COX-2i as HDT in patients with tuberculosis. CLINICAL TRIALS REGISTRATION: NCT02503839.
引用
- Nore KG, Louet C, Bugge M, et al. The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth. J Infect Dis. 2024. PMID: 37721470. doi:10.1093/infdis/jiad390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。